Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company whose news flow is closely tied to the progress of its cancer drug pipeline and capital markets activity. Press releases and updates frequently describe advances in its lead programs, including varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, and IM-1021, a ROR1-targeted antibody-drug conjugate (ADC) that uses the company’s proprietary HC74 TOP1 inhibitor payload.
Investors following IMNM news can expect detailed announcements on clinical trial milestones, such as topline data from the global Phase 3 RINGSIDE trial of varegacestat, which met its primary and key secondary endpoints in patients with progressing desmoid tumors. Immunome also issues updates on early clinical activity for IM-1021 in B-cell lymphoma, IND clearance for the FAP-targeted radioligand IM-3050, and progress across its preclinical ADC programs IM-1617, IM-1335 and IM-1340.
In addition to R&D updates, Immunome regularly reports financial and corporate developments. Recent news includes quarterly financial results, guidance on cash runway, and details of a follow-on public offering of common stock under an effective shelf registration statement. The company also discloses inducement stock option grants under its 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), as well as participation in major healthcare and investor conferences.
This IMNM news page aggregates these disclosures so readers can track trial readouts, regulatory plans such as the intended NDA submission for varegacestat, financing transactions, and corporate presentations in one place. For investors, analysts and healthcare professionals, the stream of Immunome news provides insight into the evolution of its targeted oncology pipeline and its use of capital to support ongoing development.
Immunome (Nasdaq: IMNM) reported positive topline Phase 3 RINGSIDE results for oral varegacestat in progressing desmoid tumors. The trial met the primary endpoint with a progression-free survival HR = 0.16 (84% risk reduction; 95% CI: 0.071–0.375; p<0.0001). Confirmed objective response rate was 56% vs. 9% for placebo (p<0.0001). Exploratory median best tumor volume change was -83% vs. +11% for placebo. Key secondary endpoints, including landmark tumor reduction and worst pain, were met. Varegacestat was generally well tolerated; common AEs included diarrhea (82%), fatigue (44%) and rash (43%). NDA planned for Q2 2026.
Immunome (Nasdaq: IMNM) will disclose topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors on Monday, December 15, 2025.
The company will host a live webcast and conference call on December 15, 2025 at 8:30 a.m. ET (5:30 a.m. PT) that includes presentation slides and a live Q&A following prepared remarks. The webcast is listen-only; questions must be asked via the conference call. The webcast will be archived on Immunome's investor website for 90 days.
Immunome (Nasdaq: IMNM) announced that on December 1, 2025 its Compensation Committee granted inducement non‑statutory stock options to four new employees totaling 88,000 shares under the Company’s 2024 Inducement Plan.
Each option has an exercise price of $18.32 per share (the company’s closing price on December 1, 2025) and vests over four years: 25% at the one‑year anniversary and the remainder monthly over the following 36 months, subject to continued service and the plan and option agreement terms.
Immunome (Nasdaq: IMNM) said members of management will present at two investor conferences on December 3, 2025. Presentations and times: Piper Sandler 37th Annual Healthcare Conference at 9:00 a.m. ET and Evercore 8th Annual Healthcare Conference at 9:10 a.m. ET. Interested parties can listen via live audio webcasts on the company’s Investor Relations website at www.immunome.com. Replay webcasts will be available for approximately 30 days after each live presentation.
Immunome (Nasdaq: IMNM) reported third quarter 2025 results and a program update on November 6, 2025. Cash and cash equivalents were $272.6 million as of September 30, 2025, including $44.9 million net proceeds from its at-the-market equity offering; the company expects this cash to fund operations into 2027.
Clinical highlights: topline data for the Phase 3 RINGSIDE Part B study of varegacestat is expected before end of 2025; objective responses were observed at multiple dose levels in B-cell lymphoma patients treated with IM-1021, with initial IM-1021 data planned for 2026. IND clearance for IM-3050 was received in April 2025.
Quarterly expenses included R&D of $49.2 million and G&A of $10.9 million; net loss was $57.5 million.
Immunome (Nasdaq: IMNM) announced that on Nov. 3, 2025 its Compensation Committee granted inducement stock options to three new employees under the company’s 2024 Inducement Plan.
The grants total 19,000 nonstatutory stock options with an exercise price of $17.00 per share (the company’s closing price on Nov. 3, 2025). The options vest over four years: 25% at the one-year anniversary of the vesting commencement date and the remainder vesting monthly over the following 36 months, subject to continued service, and are governed by the 2024 Inducement Plan and individual option agreements.
The Compensation Committee approved the awards as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ: IMNM) said management will present at the 2nd Annual Guggenheim Healthcare Innovation Conference on Tuesday, Nov. 11, 2025 at 8:30 a.m. ET.
Investors can listen via a live audio webcast from the company Investor Relations website at www.immunome.com. A replay will be available for approximately 30 days after the live presentation.
Immunome (Nasdaq: IMNM) presented preclinical data on Oct. 23, 2025 showing its proprietary ADC payload HC74 overcomes several ADC resistance mechanisms, including payload efflux and target heterogeneity.
The poster reported HC74 is a novel topoisomerase I inhibitor used in IM-1021 (a ROR1-targeted ADC in Phase 1) and in multiple preclinical candidates; key findings include high membrane permeability, robust bystander activity, and efficacy in preclinical models refractory or resistant to trastuzumab-DXd, irinotecan, and models with heterogeneous target expression.
A copy of the poster is available in the company’s Events & Presentations materials.
Immunome (Nasdaq: IMNM) announced that on Oct. 1, 2025 its Compensation Committee granted inducement awards of 69,000 non‑statutory stock options to purchase common stock to five new employees under the 2024 Inducement Plan.
Each option has an exercise price of $11.34 equal to the Company’s closing price on Oct. 1, 2025, and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and the terms of the 2024 Inducement Plan and the applicable stock option agreements. The grants were approved as inducements under Nasdaq Listing Rule 5635(c)(4).
Immunome (NASDAQ:IMNM) has entered into a research collaboration agreement with Infinimmune for novel antibody discovery and optimization. The partnership leverages Infinimmune's GLIMPSE™ and Anthrobody® platforms to transform early-stage antibodies into development-ready therapeutic candidates.
Under the agreement, Immunome receives target exclusivity, with Infinimmune handling antibody discovery and optimization while Immunome will manage development and commercialization of resulting candidates. Financial terms were not disclosed.